HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ICCVAM report available

This article was originally published in The Rose Sheet

Executive Summary

National Toxicology Program's Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) announces availability of "Biennial Progress Report: Interagency Coordinating Committee on the Validation of Alternative Methods: 2006-2007" in Oct. 23 Federal Register notice. Report describes ICCVAM activities, test method recommendations, and other progress made during 2006-2007 period. Notice highlights ICCVAM's recommendation of first non-animal ocular safety methods and two cell-based assays for acute poisoning, as well as its evaluation of five tests for pyrogenicity. Biennial Report can be accessed at ICCVAM Web site

You may also be interested in...



State Agencies Sharpen Supplement Market Oversight During Pandemic, With Industry's Thanks

"We're particularly concerned about the health care area right now because obviously that's driving everything now," says Tennessee AG Herbert Slatery III.  He and CRN CEO Steve Mister spoke with HBW Insight about regulation of the consumer health marketplace with FDA suspending inspections of facilities operated by businesses manufacturing and marketing products subject to its oversight.

Coronavirus Update: R&D Starts, Product Delays, Continuing Collaboration

In addition to our daily in-depth coverage of key events relating to the coronavirus pandemic, we’re bringing you a periodic round-up of other significant developments. 

Coronavirus Update: Vertex, Pfizer And Others Disclose Trial Disruptions, Viatris Merger Delayed

Clinical trials in a range of diseases continue to be impacted by concerns about patient safety and health care resources as the COVID-19 pandemic grows.

UsernamePublicRestriction

Register

RS015778

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel